Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making. Issue 9 (15th September 2017)
- Record Type:
- Journal Article
- Title:
- Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making. Issue 9 (15th September 2017)
- Main Title:
- Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making
- Authors:
- Berger, Marc L.
Sox, Harold
Willke, Richard J.
Brixner, Diana L.
Eichler, Hans‐Georg
Goettsch, Wim
Madigan, David
Makady, Amr
Schneeweiss, Sebastian
Tarricone, Rosanna
Wang, Shirley V.
Watkins, John
Daniel Mullins, C. - Abstract:
- Abstract: Purpose: Real‐world evidence (RWE) includes data from retrospective or prospective observational studies and observational registries and provides insights beyond those addressed by randomized controlled trials. RWE studies aim to improve health care decision making. Methods: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Society for Pharmacoepidemiology (ISPE) created a task force to make recommendations regarding good procedural practices that would enhance decision makers' confidence in evidence derived from RWD studies. Peer review by ISPOR/ISPE members and task force participants provided a consensus‐building iterative process for the topics and framing of recommendations. Results: The ISPOR/ISPE Task Force recommendations cover seven topics such as study registration, replicability, and stakeholder involvement in RWE studies. These recommendations, in concert with earlier recommendations about study methodology, provide a trustworthy foundation for the expanded use of RWE in health care decision making. Conclusion: The focus of these recommendations is good procedural practices for studies that test a specific hypothesis in a specific population. We recognize that some of the recommendations in this report may not be widely adopted without appropriate incentives from decision makers, journal editors, and other key stakeholders.
- Is Part Of:
- Pharmacoepidemiology and drug safety. Volume 26:Issue 9(2017)
- Journal:
- Pharmacoepidemiology and drug safety
- Issue:
- Volume 26:Issue 9(2017)
- Issue Display:
- Volume 26, Issue 9 (2017)
- Year:
- 2017
- Volume:
- 26
- Issue:
- 9
- Issue Sort Value:
- 2017-0026-0009-0000
- Page Start:
- 1033
- Page End:
- 1039
- Publication Date:
- 2017-09-15
- Subjects:
- comparative effectiveness -- decision making -- guidelines -- pharmacoepidemiology -- real‐world data -- treatment effectiveness
Pharmacoepidemiology -- Periodicals
Chemotherapy -- Periodicals
Epidemiology -- Periodicals
615.705 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/pds.4297 ↗
- Languages:
- English
- ISSNs:
- 1053-8569
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.248000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 8152.xml